for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,422.00GBp

Change

39.00(+0.53%)

Volume

307,495

Today's Range

7,333.00

 - 

7,424.00

52 Week Range

5,312.00

 - 

8,227.88

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,383.00
Open
7,355.00
Volume
307,495
3M AVG Volume
38.19
Today's High
7,424.00
Today's Low
7,333.00
52 Week High
8,227.88
52 Week Low
5,312.00
Shares Out (MIL)
1,311.78
Market Cap (MIL)
96,461.87
Forward P/E
25.96
Dividend (Yield %)
--

Next Event

AstraZeneca PLC Investor Roadshow - UK, London

Latest Developments

More

AstraZeneca Releases Subgroup Analysis of TWILIGHT Trial Patients With NSTE-ACS

AstraZeneca Says Consistent Effects Of FARXIGA In Heart Failure Patients With Reduced Ejection Fraction Shown In New Analyses

AstraZeneca Says Qtrilmet Approved In The EU For Treatment Of T2D

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.18 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.5K

2018

22.1K

2019(E)

24.2K
EPS (USD)

2016

4.310

2017

4.280

2018

3.460

2019(E)

3.581
Price To Earnings (TTM)
59.12
Price To Sales (TTM)
5.18
Price To Book (MRQ)
10.27
Price To Cash Flow (TTM)
21.77
Total Debt To Equity (MRQ)
149.28
LT Debt To Equity (MRQ)
144.53
Return on Investment (TTM)
4.49
Return on Equity (TTM)
3.26

Latest News

Latest News

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study.

Britain's AstraZeneca launches $1 billion China investment fund with CICC

AstraZeneca <AZN.L> said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

AstraZeneca to distribute Sun Pharma cancer drugs in China

Top Indian drugmaker Sun Pharmaceutical Industries Ltd <SUN.NS> said on Wednesday Britain's AstraZeneca <AZN.L> would distribute some of Sun's cancer treatment drugs in China, the world's second-largest pharmaceutical market.

Britain's AstraZeneca to distribute Sun Pharma cancer drugs in China

Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday it would introduce some of its cancer treatment drugs in China through Britain's AstraZeneca.

AstraZeneca sells European rights for schizophrenia drug to Cheplapharm

AstraZeneca Plc <AZN.L> said on Wednesday it plans to sell the European and Russian rights for a schizophrenia drug to German firm Cheplapharm Arzneimittel for an upfront payment of $178 million, as the British drugmaker looks to offload older drugs.

AstraZeneca's combo drug for lung cancer succeeds in late-stage trial

AstraZeneca Plc said on Monday a combination of its cancer drug, Imfinzi, along with chemotherapy helped curb progression of lung cancer in a late-stage study, sending its shares up as much as 2%.

AstraZeneca cancer drug combo meets late-stage trial goal

AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.

AstraZeneca raises sales forecast after surge in cancer drugs

AstraZeneca <AZN.L> lifted its annual drug sales forecast for the second time this year after a surge in revenue from newer cancer treatments, but warned that changing policies in China, its second-biggest market, would crimp growth next year.

FTSE 100 heads for fourth session of gains

London's FTSE 100 held firm at a near one-month high on Thursday as gains in AstraZeneca after a 2019 target upgrade countered losses in Royal Bank of Scotland following a weak third-quarter update, while midcaps outperformed as sterling rose.

AstraZeneca tops sales forecasts on China, new drug boosts

AstraZeneca Plc reported better-than-expected third-quarter product sales on Thursday, on the back of strong demand for newer medicines including cancer treatments Tagrisso and Lynparza as well as growth in China.

U.S. FDA okays wider use of GSK ovarian cancer drug

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

U.S. FDA approves AstraZeneca diabetes drug for treating heart failure risk

AstraZeneca's <AZN.L> diabetes drug Farxiga has been approved for use in the United States as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks, the British drugmaker said on Monday.

U.S. FDA approves AstraZeneca's diabetes drug for treating heart failure risk

AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.

AstraZeneca breast cancer treatment gets FDA priority review

AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG.

AstraZeneca gets FDA priority review for experimental breast cancer drug

Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of next year.

FDA green lights AstraZeneca's asthma drug Fasenra for self-administration

British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen.

AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm

AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million.

AstraZeneca's combo lung disease therapy fails to win FDA approval

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's <AZN.L> combination therapy to treat smoker's lung, the drugmaker said on Tuesday.

AstraZeneca's combo lung disease therapy falls short of FDA approval

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.

AstraZeneca strengthens Lynparza push with prostate cancer data

AstraZeneca <AZN.L> presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up